Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$39.50 – $60.85
73% from low
Exchange
OTC Link
ADRC
P/S (TTM)
3.3
EV / FCF (TTM)
12.9
ROCHE HOLDING LTD S/ADR
No one on the platform currently holds RHHBY.
No tracked institution reports a position in RHHBY as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-03-13 | $1.5495 | 2026-04-22 |
| 2025-03-28 | $1.3890 | 2025-05-14 |
| 2024-03-14 | $1.3494 | 2024-05-03 |
| Execution date | Ratio |
|---|---|
| 2014-02-27 | 2-for-1 |
| 2009-01-09 | 2-for-1 |
No one on the platform has traded RHHBY yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 24.3% | 24.7% | 29.6% | — | — | — |
| Rev. Growth % | 1.5% | 1.7% | ||||
| Profit Margin % | 20.3% | 18.7% | 19.1% | |||
| Free Cash Flow Margin % | 21.2% | 22.0% | 23.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +3.0% on the P/E track.
At today's price, your expected annual return is +8.1% on the P/E track.
At today's price, your expected annual return is +13.0% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $61.6B | -0.6% | $2.49 | $2.13–$2.61 | 22.1× | 5 |
| 2027 | $64.3B | +4.3% | $2.67 | $2.34–$2.79 | 20.6× | 5 |
| 2028 | $67.4B | +4.8% | $2.90 | $2.77–$3.04 | 19.0× | 2 |
| 2029 | $70.3B | +4.4% | $3.14 | $3.00–$3.30 | 17.5× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-23 | $1.58 | $1.66 | +5.1% |
| 2026-01-29 | $1.35 | $1.36 | +0.7% |
| 2025-07-24 | $1.62 | $1.74 | +7.4% |
| 2025-01-30 | $1.17 | $1.18 | +0.9% |
| 2024-07-22 | $1.30 | $1.43 | +10.0% |
| 2024-02-01 | $1.22 | $1.23 | +0.8% |
| 2023-07-27 | $1.49 | $1.45 | -2.7% |
| 2023-02-02 | $1.19 |
| $1.14 |
| -4.2% |
| +3.68% |
| $33.3B |
| — |
| DSNKYDaiichi Sankyo Company, Limited | $18.40 | +1.60% | $33.5B | — |
| GLAXFGSK plc | $24.00 | +0.00% | $96.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Raymond James⬆️ $SRRK's PT to $72 vs $65 and reit'd Strong Buy ~ sees rapid ISEMBYLD US uptake—ests. $2.2B revenue on 50% penetration in 2035: $BIIB - IONS $RHHBY - PTCT NVS Truist⬆️Scholar Rock's PT to $76 vs $55 and reit'd Buy ~ Based on its due-diligence including prior KOL checks, they continue to believe in broad uptake of the drug in combination with SMN2. Here's what Raymond James said in its note: https://x.com/Quantumup1/status/2099442394156388539?s=20
View on StockTwits ↗
$IFRX Awesome to see short 12.3m this morning. A 32% increase from just 30 days ago (+3m shares). Based on last 10 trading days volume —-it wld take 19.3 days to cover 12.3m The funds who bought did so for a reason —-and around current pricing + / -$2. They buy for 10-20x They bought because $AMGN has an FDA approved drug that used fraud in its datasets. Already removed from UK and Europe, it’s eventually gonna be removed in “litigation friendly” US. The longer it takes, the better for Inflarx. A proven backup is in the wings. #LiverTox optics can’t look great for Amgen. $BIIB $RHHBY $PFE gotta be looking.
View on StockTwits ↗BMO Capital reiterated $SRRK Outperform-$76 and said -- Physician Expert Survey Supports Broad Uptake of Apitegromab in SMA $RHHBY $NVS BIIB - IONS PTCT LLY NVO BMY REGN BMO Capital added—Proprietary physician survey points to broad potential usage of Scholar Rock's apitegromab on top of SMN-directed therapy for patients with spinal muscular atrophy (SMA). Key takeaways from neurologist survey (n = 15) 1) Broad potential eligibility, with 62% of SMN-treated patients viewed as candidates; 2) strong physician interest, with 73% of surveyed physicians planning to prescribe within six months; and 3) adoption driven primarily by motor-function improvement and clean safety. These results support our bullish view of Scholar Rock shares into the September 30, 2026, PDUFA.
View on StockTwits ↗
$NVS $LXRX $BMY $MRK $RHHBY 🚨 ATTENTION CEOs & BIOTECH LEADERS! 🚨 LOOKING TO EXPAND YOUR ONCOLOGY AI DATA CAPABILITIES? 🧬🤖 $LXRX HAS A MASSIVE, DECADES-LONG GENOMIC DATASET THAT COULD OFFER A POWERFUL OPPORTUNITY FOR AI-DRIVEN ONCOLOGY RESEARCH. IF YOU’RE LOOKING TO PARTNER, THIS IS ONE TO WATCH. 🤝🔥 $LXRX is evaluating AI to unlock the potential of its massive Genome 5,000 database, built from decades of structured and unstructured genomic data. 🧬🤖 - Lexicon's CEO Mike Exton 09/09/2026 The goal: automate data searches and rapidly uncover new opportunities, including in oncology—a space the company has barely explored. 🚀 Potentially a very interesting asset for future oncology partnerships. 🤝 ....
View on StockTwits ↗
$BIIB $CLNN $QNTM $RHHBY $SNY From the article: “Clene Inc. (NASDAQ: CLNN) shared results from new analyses examining clinical outcomes among CNM-Au8(R)-treated patients whose neurofilament light chain (“NfL”) biomarker levels declined or stabilized. These findings will be included in Clene’s planned New Drug Application (“NDA”) seeking accelerated approval and are intended to address the questions raised by the U.S. Food and Drug Administration (“FDA”) during a March 2026 Type C meeting. At that meeting, the FDA acknowledged that NfL, a recognized blood marker of nerve-cell injury, has established prognostic value in amyotrophic lateral sclerosis (“ALS”) and could potentially serve as a reasonably likely surrogate endpoint to support accelerated approval.”
View on StockTwits ↗
$MRK $BMY $ABBV $RHHBY $NVS Under the radar Midcap Oncology Biotech TLK has PDUFA Date on the day after tomorrow (Friday). If Approved, TLK could go parabolic but no promises.
View on StockTwits ↗
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach $QNTM $SNY $RHHBY $BIIB $CLNN https://ibn.fm/MrHnd
View on StockTwits ↗
$RHHBY https://www.dailymail.com/news/article-16106001/Healthy-middle-aged-Britons-offered-Alzheimers-drug-trial-aiming-prevent-dementia.html
View on StockTwits ↗
Go for it Roche Genentech! $LCTX $RHHBY #Opregen The #regenerative medicine "Replace and Restore" cellular approach!
View on StockTwits ↗$IFRX Hot off the press is Oppenheimer today w reiterattion of $9 target on removal of $AMGN Tavenos by MHRA (UK). Heads I win, Tails you lose mentality cited: “US withdrawal process is ongoing. Amgen filed its hearing response to the FDA's proposed Taveneos withdrawal on July 23. ***** The contested process is expected to extend well into 2027, but IFRX remains advantaged under either outcome: withdrawal creates a greenfield, while continued availability lets Amgen build the market for a potentially better-tolerated oral C5aR inhibitor in izicopan.**** How long before Tavneos could be removed from the US market? There is no direct precedent; Tavneos is the first fully approved drug facing withdrawal over pivotal data manipulation.” $BIIB $PFE $RHHBY
View on StockTwits ↗
$KZIA Lots of news out today along with a conference call going on now. The news here is beyond exciting when you consider this is clearly the best in class PI3K/MTOR inhibitor and has just now opened up new indications. This will soon enough be a multi-billion dollar drug and the current market cap (fully diluted) is under $300M. REalize that when I say fully diluted, that would mean they have $140M of cash if the warrants are exercised. Fully funded and off to the races. Thanks for sharing this drug with us $RHHBY . Coming after you $CELC .
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.